Oragenics director sells shares, gets 125,000 options

Q: What insider transactions did Oragenics (OGEN) report in this Form 4/A?

The filing shows director Fred Telling sold 210 shares of Oragenics common stock at a weighted average price of $0.9446 and received an award of 125,000 stock options with a $0.93 exercise price.

Q: How many Oragenics (OGEN) shares does the director hold after the reported sale?

After selling 210 shares, the director beneficially owned 948 shares of Oragenics common stock directly, according to the amended report.

Q: What are the key terms of the 125,000 Oragenics (OGEN) stock options?

The 125,000 non-employee director options have an exercise price of $0.93 per share, vest immediately, and expire on 12/11/2035, and relate to Oragenics common stock.

Q: Why did Oragenics (OGEN) file this Form 4/A amendment?

The amendment states it was filed to correct the amount of securities beneficially owned after a 1-for-30 reverse stock split of Oragenics common stock that was not reflected in the prior filing.

Oragenics, Inc. director Fred Telling filed an amended insider trading report covering a small stock sale and a new option grant.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

4/A

Rhea-AI Filing Summary

Oragenics, Inc. director Fred Telling filed an amended insider trading report covering a small stock sale and a new option grant. On 12/12/2025, he sold 210 shares of common stock at a weighted average price of $0.9446, and held 948 shares directly after the transaction. The filing notes that the shares were sold in multiple trades between $0.9440 and $0.9451.

The amendment also reports a grant of 125,000 non-employee director stock options on 12/11/2025 with an exercise price of $0.93 per share, vesting immediately and expiring on 12/11/2035. The company previously completed a 1-for-30 reverse stock split of its common stock, and this amendment corrects the amount of securities beneficially owned to reflect that corporate action.

Insider Trade Summary

Net Seller: 210 shares

Net Sell 2 txns

Insider Telling Fred

Role Director

Sold 210 shs ($198.37)

Type	Security	Shares	Price	Value
Sale	Common Stock	210	$0.9446	$198.37
Grant/Award	Non-Employee Director Option (Right to Buy)	125,000	$0.00	$0.00

Holdings After Transaction: Non-Employee Director Option (Right to Buy) — 125,000 contracts (Direct); Common Stock — 948 shares (Direct)

Footnotes (3)

F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.9440 to $0.9451. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F2. This Amendment is being filed to correct the amount of securities beneficially owned. The Issuer effected a 1-for-30 reverse stock split of its outstanding common stock, which was not reflected on the prior Form 4.
F3. Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Oragenics (OGEN) report in this Form 4/A?

The filing shows director Fred Telling sold 210 shares of Oragenics common stock at a weighted average price of $0.9446 and received an award of 125,000 stock options with a $0.93 exercise price.

How many Oragenics (OGEN) shares does the director hold after the reported sale?

After selling 210 shares, the director beneficially owned 948 shares of Oragenics common stock directly, according to the amended report.

What are the key terms of the 125,000 Oragenics (OGEN) stock options?

The 125,000 non-employee director options have an exercise price of $0.93 per share, vest immediately, and expire on 12/11/2035, and relate to Oragenics common stock.

Why did Oragenics (OGEN) file this Form 4/A amendment?

The amendment states it was filed to correct the amount of securities beneficially owned after a 1-for-30 reverse stock split of Oragenics common stock that was not reflected in the prior filing.

Over what price range were Oragenics (OGEN) shares sold in this insider transaction?

The 210 shares were sold in multiple transactions at prices ranging from $0.9440 to $0.9451, with a weighted average price of $0.9446.

Is the Oragenics (OGEN) director transaction under a Rule 10b5-1 plan?

The form includes a checkbox referencing transactions made under a Rule 10b5-1(c) trading plan, but the excerpt does not indicate that this specific transaction box was checked.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 01/22/2026 - 01:04 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Telling Fred

(Last)

(First)

(Middle)

9015 TOWN CENTER PARKWAY, SUITE 143

(Street)

LAKEWOOD RANCH

34202

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ORAGENICS INC [ OGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
12/15/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	12/12/2025		S		210	D	$0.9446⁽¹⁾	948⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Employee Director Option (Right to Buy)	$0.93	12/11/2025		A		125,000⁽³⁾		12/11/2025⁽³⁾	12/11/2035	Common Stock	125,000	$0	125,000⁽³⁾	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.9440 to $0.9451. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

2. This Amendment is being filed to correct the amount of securities beneficially owned. The Issuer effected a 1-for-30 reverse stock split of its outstanding common stock, which was not reflected on the prior Form 4.

3. Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant.

	/s/ Julio C. Esquivel as Attorney-In-Fact for Fred Telling	01/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR